Wednesday, 21 Aug 2019

You are here

Zolendronate Protects Against Fracture in Osteopenia

The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.

While it is known that bisphonates have beneficial effects in osteoporosis, their impact in osteopenia has not been shown. 

A 6-year, double-blind trial involving 2000 elderly women (>65 yrs)  with osteopenia (T score −1.0 to −2.5)in the hip or femoral neck were randomized to receive four infusions of zoledronate (5 mg) or saline (placebo group) at 18-month intervals. The primary end point was the time to first occurrence of a nonvertebral or vertebral fragility fracture.

The baseline age was 71±5 years, T score was −1.6±0.5, and the 10-year risk of hip fracture was 2.3%.

A fragility fracture occurred in 190 women in the placebo group and in 122 women in the zoledronate group (hazard ratio with zoledronate, 0.63; 95% confidence interval, 0.50 to 0.79; P<0.001).

The NNT to prevent a fracture in 1 woman was 15.

Women treated with zoledronate had a lower risk of nonvertebral fragility fractures (hazard ratio, 0.66), symptomatic fractures (HR 0.73), vertebral fractures (OR 0.45) and height loss (P<0.001).

The bisphosphonate, zoledronate (zoledronic acid) is marketed by Novartis under the of Reclast.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Bisphosphonate Use Associated with Reduced Mortality

The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.

Accelerated bone loss has been shown to be an independent predictor of mortality risk, but the relationship between bisphosphonates, bone loss, and mortality is unknown.

Partial or Total Knee Replacement for Osteoarthritis?

Lancet has reported on a clinical trial comparing total knee replacement (TKR) and partial knee replacement (PKR) in late-stage isolated medial compartment knee osteoarthritis patients finding that both TKR and PKR are equally effective, PKR should be considered the first, because of lower costs and better cost-effectiveness.

Intraarticular Capsaicin in Knee Osteoarthritis

A novel compound, synthetic trans‐capsaicin (CNTX‐4975), has been studied as an intraarticular injection and shown to significantly reduce pain in patients with chronic moderate‐to‐severe osteoarthritis of the knee. A phase II, multicenter, double‐blind study enrolled 172 knee OA patients between the ages of 45–80 years. Patients were randomized to receive either intraarticular placebo, or a high‐purity synthetic trans‐capsaicin CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg.

Increased Risk of Cardiovascular Death in Hip and Knee Osteoarthritis

Hip and knee osteoarthritis patients have been shown to have increased mortality rates from cardiovascular events when compared to the general population.

The study included patients in the Skåne Healthcare Register from southern Sweden who were 45–84 years old and seen over 2004-2014. Overall, there were 15,901 such patients in the study.

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.